Lessons from PROMINENT and prospects for pemafibrate

作者：Jean‐Charles Fruchart, Jamila Fruchart‐Najib, Shizuya Yamashita, Peter Libby, Koutaro Yokote, Tatsuhiko Kodama, Yohei Tomita, Paul M. Ridker, Michel P. Hermans, Alberto Zambon · 发表于：Cardiovascular Diabetology · 年份：2024 · DOI：10.1186/s12933-024-02305-z · 被引用次数：14 · 研究领域：Liver Disease Diagnosis and Treatment、Diabetes Treatment and Management、Lipid metabolism and disorders

The neutral result of the PROMINENT trial has led to questions about the future for pemafibrate. This commentary discusses possible reasons for the lack of benefit observed in the trial. There were, however, indicators suggesting therapeutic potential in microvascular ischaemic complications associated with peripheral artery disease, with subsequent analysis showing reduction in the incidence of lower extremity ischaemic ulceration or gangrene. Reassurance about the safety of pemafibrate, together with emerging data from PROMINENT and experimental studies, also suggest benefit with pemafibrate in non-alcoholic fatty liver disease (alternatively referred to as metabolic dysfunction-associated steatotic liver disease) and microangiopathy associated with diabetes, which merit further study.